Bafna Pharma.

What does Bafna Pharma. do?

Bafna Pharmaceuticals Ltd manufactures pharmaceutical formulations, focusing on Betalactum and Non Betalactum products. Established in 1981, it operates as a micro-cap company with a market cap of Rs 176 Cr and reported net sales of 39 Cr and a net profit of 1 Cr for the quarter ending March 2025.

Overview:<BR>Bafna Pharmaceuticals Ltd is engaged in the manufacturing of pharmaceutical formulations, specializing in both Betalactum and Non Betalactum products, and operates within the Pharmaceuticals & Biotechnology industry as a Micro Cap company.<BR><BR>History:<BR>Bafna Pharmaceuticals Ltd was established in 1981 by Mr. Bafna Mahaveer Chand. The company initially operated as a proprietary concern and set up its first manufacturing unit in Madhavaram (Chennai) in October 1984. The latest financial results reported are for the quarter ending March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 39 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 1 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 176 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 28.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.21<BR>- Return on Equity: 7.63%<BR>- Price to Book: 2.13<BR><BR>Contact Details:<BR>Address: Bafna Towers New No 68, Old No 299 Thambu Chetty St Chennai Tamil Nadu : 600001<BR>Tel: 91-44-25267517/25270992/4267755<BR>Email: info@bafnapharma.com<BR>Website: http://www.bafnapharma.com

Who are in the management team of Bafna Pharma.?

As of March 2022, Bafna Pharma's management team includes Shanmugam Hemalatha (Chairperson/Executive Director), Vinayak Dinesh Dendukuri (Whole Time Director), and several non-executive directors, along with company secretaries and compliance officers. The team features a mix of executive and non-executive roles.

As of March 2022, the management team of Bafna Pharma includes the following individuals:<BR><BR>1. Babulal Kamlesh Kumar - Non-Executive & Independent Director<BR>2. Shanmugam Hemalatha - Chairperson / Executive Director<BR>3. Akilapriya Chandrashekar Raju - Non-Executive & Non-Independent Director<BR>4. Palamadai Krishnan Sundaresan - Non-Executive & Independent Director<BR>5. Ravichandran Chitra - Non-Executive & Independent Director<BR>6. Atul Sachdeva - Non-Executive & Non-Independent Director<BR>7. Roopa Ravikumar - Company Secretary<BR>8. Vishnu Vasudeva Kuppa - Company Secretary & Compliance Officer<BR>9. Upendar Mekala Reddy - Additional Non-Independent Director<BR>10. Krishna Yeachuri - Additional Non-Executive Director & Independent Director<BR>11. Vinayak Dinesh Dendukuri - Whole Time Director (Operations)<BR>12. Upendar Mekala Reddy - Additional Director<BR>13. Krishna Yeachuri - Additional Director<BR><BR>This team comprises a mix of executive and non-executive directors, along with key administrative roles.

Has Bafna Pharma. declared dividend?

Bafna Pharmaceuticals Ltd has declared a 6% dividend, amounting to 0.6 per share, but the dividend yield is 0%. Despite the recent negative returns over shorter periods, the company has shown a significant positive return of 647.95% over the past five years.

Bafna Pharmaceuticals Ltd has declared a 6% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 6%<BR>- Amount per share: 0.6<BR>- Ex-date: 19 Sep 13<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -10.98%, the dividend return was 0%, resulting in a total return of -10.98%.<BR><BR>Over the past year, the price return was -14.66%, with a dividend return of 0%, leading to a total return of -14.66%.<BR><BR>In the 2-year period, the price return was -41.86%, the dividend return remained at 0%, culminating in a total return of -41.86%.<BR><BR>For the 3-year period, the price return was -40.07%, with no dividend return, resulting in a total return of -40.07%.<BR><BR>In the last 4 years, the price return was -46.01%, the dividend return was 0%, which resulted in a total return of -46.01%.<BR><BR>Over the 5-year period, the price return was 647.95%, with a dividend return of 0%, leading to a total return of 647.95%.<BR><BR>Overall, while Bafna Pharmaceuticals Ltd has declared a dividend, the dividend yield is 0%, indicating that the dividend has not contributed to returns in recent periods. The total returns show significant volatility, with a stark contrast between the short-term negative returns and the long-term positive return over five years.

Who are the peers of the Bafna Pharma.?

Bafna Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Murae Organisor, Krebs Biochem, Auro Labs, and Bal Pharma. Bafna Pharma has below average management risk, good growth, and a return of -11.19%, significantly lower than its peers.

Peers: The peers of Bafna Pharma. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Murae Organisor, Krebs Biochem, Auro Labs., and Bal Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Below Average management risk is found at Murae Organisor and Bafna Pharma., and Average management risk is noted at Bal Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Murae Organisor, while Good growth is seen at Bafna Pharma. and Bal Pharma, and Below Average growth is reported for Divi's Lab. and Torrent Pharma. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is found at Bafna Pharma. and Auro Labs., and Below Average capital structure is observed at Murae Organisor and Bal Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while Bafna Pharma. has the lowest at -11.19%. Compared to its peers, Bafna Pharma.'s return is significantly lower. Additionally, the six-month return is negative for Sun Pharma.Inds., Torrent Pharma, Dr Reddy's Labs, Murae Organisor, Krebs Biochem, Bal Pharma, and Bafna Pharma.

What is the technical trend for Bafna Pharma.?

As of June 4, 2025, Bafna Pharma's technical trend is bearish across multiple time frames, with bearish signals from MACD, Bollinger Bands, and moving averages, despite a mildly bullish indication from Dow Theory.

As of 4 June 2025, the technical trend for Bafna Pharma has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple time frames. The MACD is bearish on both the weekly and monthly charts, and Bollinger Bands also reflect a bearish trend in the same time frames. Daily moving averages confirm a bearish outlook. The KST is bearish on both weekly and monthly levels. Although the Dow Theory shows a mildly bullish signal on the weekly chart, the overall technical indicators suggest a prevailing bearish sentiment. The stock is currently priced at 75.00, with a recent high of 75.00 and a low of 75.00 today, indicating a lack of volatility.

Who are the top shareholders of the Bafna Pharma.?

The top shareholder of Bafna Pharma is Srjr Lifesciences LLP, holding 74.57%. Other notable shareholders include three foreign institutional investors with 8.53% and individual investor Alpana Mundra with 2.91%, while there are no pledged promoter holdings or mutual fund investments.

The top shareholders of Bafna Pharma include the promoters, with Srjr Lifesciences LLP holding the highest stake at 74.57%. Additionally, there are three foreign institutional investors (FIIs) who collectively hold 8.53%. On the public side, Alpana Mundra is the largest individual shareholder with a 2.91% stake, while individual investors overall account for 11.06% of the company's shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

How big is Bafna Pharma.?

As of 24th July, Bafna Pharmaceuticals Ltd has a market capitalization of 212.00 Cr, with recent net sales of 27.26 Cr and a net loss of 4.00 Cr. Shareholder's funds were 51.11 Cr, and total assets were valued at 71.31 Cr as of March 2020.

As of 24th July, Bafna Pharmaceuticals Ltd has a market capitalization of 212.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Bafna Pharmaceuticals reported Net Sales of 27.26 Cr. However, the company experienced a loss of 4.00 Cr in Net Profit over the same period.<BR><BR>The latest annual period for the balance sheet is March 2020, where Shareholder's Funds amounted to 51.11 Cr and Total Assets were valued at 71.31 Cr.

Are Bafna Pharma. latest results good or bad?

Bafna Pharmaceuticals' latest results are positive, showing a net profit of ₹3.17 crore in Q2 FY26, a recovery from a loss last year, and a 68.91% increase in net sales. However, concerns remain about the sustainability of this performance due to ongoing negative operating profit.

Bafna Pharmaceuticals' latest results indicate a significant improvement in performance, marking a positive turnaround for the company. In Q2 FY26, the company reported a net profit of ₹3.17 crore, a notable recovery from a loss of ₹0.59 crore in the same quarter last year. This shift to profitability is particularly encouraging given the company's historical struggles with consistent losses.<BR><BR>Additionally, the company experienced a substantial 68.91% increase in net sales compared to the previous quarter, reaching ₹11.57 crore. Year-over-year, this represents a 30.88% growth, showcasing improved operational execution and potentially favorable market conditions.<BR><BR>However, while the return to profitability is a positive sign, there are concerns regarding the sustainability of this performance. The operating profit, excluding other income, remained negative at ₹0.37 crore, although this was an improvement from the previous quarter's loss. The dependency on other income for profitability raises questions about the core business's ability to generate consistent earnings.<BR><BR>Overall, while the latest results are good in terms of achieving profitability and revenue growth, the company still faces challenges in operational efficiency and margin improvement. Investors should monitor these aspects closely as the company navigates its turnaround journey.

Is Bafna Pharma. overvalued or undervalued?

As of November 27, 2025, Bafna Pharma is considered overvalued with a valuation grade of expensive, reflected in its high PE ratio of 34.67 and EV to EBITDA of 25.19, despite a strong year-to-date return of 102.48%.

As of 27 November 2025, the valuation grade for Bafna Pharma has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 34.67, an EV to EBITDA of 25.19, and a ROE of 12.46%. <BR><BR>In comparison to peers, Sun Pharma has a higher PE ratio of 37.62 and an EV to EBITDA of 24.87, while Cipla, which is rated attractive, has a significantly lower PE of 22.67 and an EV to EBITDA of 16.04. Despite a strong year-to-date return of 102.48% compared to the Sensex's 9.70%, the high valuation ratios suggest that Bafna Pharma's stock price may not be justified at current levels.

How has been the historical performance of Bafna Pharma.?

Bafna Pharma has experienced a significant decline in financial performance, with net sales dropping from INR 185.34 crore in March 2014 to INR 43.36 crore in March 2019, and consistent losses in operating profit, profit before tax, and profit after tax since 2015. The company's total assets and cash flow from operating activities have also decreased, indicating a challenging financial period.

Answer:<BR>The historical performance of Bafna Pharma has shown a declining trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Bafna Pharma's net sales have decreased significantly from INR 185.34 crore in March 2014 to INR 43.36 crore in March 2019. The total operating income followed a similar downward trajectory, dropping from INR 185.34 crore in March 2014 to INR 43.36 crore in March 2019. The company's total expenditure, excluding depreciation, also fell from INR 162.50 crore in March 2014 to INR 56.70 crore in March 2019. Operating profit (PBDIT) has been negative since March 2016, with a loss of INR 13.34 crore reported in March 2019. Profit before tax has consistently been negative since March 2015, culminating in a loss of INR 17.28 crore in March 2019. The profit after tax has also remained negative, with a loss of INR 18.35 crore in March 2019. The company's total assets decreased from INR 199.83 crore in March 2015 to INR 71.31 crore in March 2020, while total liabilities dropped from INR 199.83 crore to INR 71.31 crore in the same period. Cash flow from operating activities has been negative since March 2016, with a cash outflow of INR 34.00 crore in March 2020. Overall, Bafna Pharma's financial performance reflects a challenging period with declining revenues and increasing losses.

Should I buy, sell or hold Bafna Pharmaceuticals Ltd?

When is the next results date for Bafna Pharmaceuticals Ltd?

The next results date for Bafna Pharmaceuticals Ltd is 11 February 2026.

The next results date for Bafna Pharmaceuticals Ltd is scheduled for 11 February 2026.

Why is Bafna Pharmaceuticals Ltd falling/rising?

As of 08-Feb, Bafna Pharmaceuticals Ltd's stock price is rising today despite a 21.46% decline over the past month, with a notable profit growth of 189.33% in the last six months. However, the stock's long-term outlook is challenged by bearish trends and a significant drop in investor participation.

As of 08-Feb, Bafna Pharmaceuticals Ltd's stock price is currently rising, as indicated by a change of 0.21 (0.18%) upward. This increase comes despite a challenging performance over the past month, where the stock has declined by 21.46%. However, the stock has outperformed the sector today by 0.98%, suggesting a positive short-term momentum.<BR><BR>The company's recent financial performance shows significant growth, with a profit after tax (PAT) of Rs 6.51 crore, which has grown at an impressive rate of 189.33% over the last six months. Additionally, the operating cash flow has reached its highest at Rs 22.14 crore, indicating strong operational efficiency. The stock is also trading at a discount compared to its peers' average historical valuations, which may attract investors looking for value.<BR><BR>Furthermore, over the past year, Bafna Pharmaceuticals has generated a return of 45.56%, significantly outperforming the broader market, which has returned only 7.71%. This strong annual performance, coupled with a low PEG ratio of 0, suggests that the stock may be undervalued relative to its growth potential.<BR><BR>However, it is important to note that the stock is trading below its moving averages across various time frames, indicating a potential bearish trend in the longer term. Additionally, there has been a drastic decline in investor participation, with delivery volume falling by 97.91% against the 5-day average, which could signal a lack of confidence among investors.<BR><BR>In summary, while Bafna Pharmaceuticals Ltd is experiencing a rise in its stock price today, the overall context includes significant short-term gains against a backdrop of longer-term challenges and declining investor interest.

Which are the latest news on Bafna Pharma.?